Related Experiment Video
Updated: Aug 21, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Suppression of immune system genes by methylprednisolone in exacerbations of multiple sclerosis. Preliminary results
Nina Airla1, Mari Luomala, Irina Elovaara
1Tampere University Hospital, Centre for Laboratory Medicine, Laboratory of Atherosclerosis Genetics Finn-Medi 2, 3rd Floor, P. O. Box 2000, 33521 Tampere, Finland. nina.airla@uta.fi
Abstract:
Acute relapses of multiple sclerosis (MS) are treated with intravenous methylprednisolone (IVMP), which speeds recovery from exacerbation. It is known that IVMP suppresses the immunological activation which occurs during an acute attack of MS. However, the specific target genes affected by this therapy remain obscure. A cDNA microarray for 448 genes was used to identify the target genes in IVMP therapy. Total RNA was isolated from peripheral blood mononuclear cells derived from six MS patients immediately before and after completion of therapy. IVMP significantly reduced mRNA levels for T-cell-specific transcription factor 7 (p=0.02), T-cell-specific protein-tyrosine kinase (p=0.02), T-cell surface glycoprotein CD5 (p=0.05) and interferon-stimulated gene factor 3 gamma subunit (p=0.04). Significantly increased expression was found for eosinophil-derived neurotoxin (p=0.05). The suppression of expression of genes associated with T-cell differentiation and antigen-specific T-cell activation detected in this study may contribute to the beneficial effect of MP in relapses of MS.
Insights
Intravenous methylprednisolone (IVMP) speeds recovery from multiple sclerosis (MS) relapses by suppressing immune activation. This study identified specific genes, including T-cell factors, reduced by IVMP, potentially explaining its therapeutic benefits.
Area of Science:
- Immunology
- Neuroscience
- Genetics
Background:
- Acute relapses of multiple sclerosis (MS) are commonly treated with intravenous methylprednisolone (IVMP) to accelerate recovery.
- While IVMP is known to suppress immune activation during MS exacerbations, the precise molecular targets remain largely unknown.
Purpose of the Study:
- To identify specific genes modulated by IVMP therapy in patients experiencing acute MS relapses.
- To elucidate the molecular mechanisms underlying the therapeutic effects of IVMP in MS.
Main Methods:
- Utilized a cDNA microarray encompassing 448 genes to analyze gene expression changes.
- Isolated total RNA from peripheral blood mononuclear cells (PBMCs) of six MS patients before and after IVMP treatment.
Main Results:
- IVMP significantly downregulated mRNA levels of T-cell-specific transcription factor 7, T-cell-specific protein-tyrosine kinase, T-cell surface glycoprotein CD5, and interferon-stimulated gene factor 3 gamma subunit.
- A significant upregulation was observed in the expression of eosinophil-derived neurotoxin.
Conclusions:
- The observed suppression of genes involved in T-cell differentiation and antigen-specific activation suggests a key mechanism for IVMP's efficacy in managing MS relapses.
- These findings provide novel insights into the molecular targets of IVMP, contributing to a better understanding of MS pathophysiology and treatment.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:19Multiple Sclerosis l: Introduction